dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact.
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
To date, there are no methods to reliably select which patients with non-squamous non-small
cell lung cancer (NSCLC) that benefit most from treatment with bevacizumab. Data have shown
that high levels of plasma VEGF are prognostic and correlates with a worse disease outcome in
some tumour types, including advanced NSCLC.
Recent data are suggestive of a predictive value of imaging techniques for early detection of
antiangiogenic treatment efficacy in different cancers. To our knowledge there are no
presented data available on correlation between changes in diffusion-weighted MR and response
to bevacizumab treatment in lung cancer. The current study is designed as a pilot study to
prospectively investigate changes in MR variables during treatment with bevacizumab and to
detect signals of prognostic and/or predictive value of MR changes during treatment.